News - Press Releases & Alerts


Press Releases & Alerts

July 13, 2012
IPQ mentioned in Reuters Article: "Vivus: Consensus Calls For FDA Approval, But Watch For Label Restrictions".
In this article IPQ correctly predicted that the FDA would approve Qsymia but with a more restricted labeling than sought by Vivus, pending additional post-marketing surveillance, approval of the REMS and CVOT plans, possible requirement for a patient registry and restricted prescribing quantities, ongoing patient testing, etc. Download PDF